JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

NVS

121.06

+0.67%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

NVS

121.06

+0.67%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

NVS

121.06

+0.67%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

NVS

121.06

+0.67%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

NVS

121.06

+0.67%↑

Search

Eli Lilly and Co.

Gesloten

SectorGezondheidszorg

779.27 0.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

774.1

Max

782.51

Belangrijke statistieken

By Trading Economics

Inkomsten

-6.1B

2.8B

Verkoop

-804M

13B

K/W

Sectorgemiddelde

62.756

50.291

EPS

3.34

Dividendrendement

0.79

Winstmarge

21.678

Werknemers

47,000

EBITDA

-2B

4.2B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.9% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.79%

2.40%

Volgende Winsten

6 aug 2025

Volgende dividenddatum

10 sep 2025

Volgende Ex Dividend datum

15 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-136B

692B

Vorige openingsprijs

778.91

Vorige sluitingsprijs

779.27

Nieuwssentiment

By Acuity

48%

52%

161 / 380 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Eli Lilly and Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 jun 2025, 11:56 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27 mei 2025, 14:41 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

17 jun 2025, 14:02 UTC

Acquisities, Fusies, Overnames

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 jun 2025, 12:12 UTC

Acquisities, Fusies, Overnames

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 jun 2025, 11:01 UTC

Acquisities, Fusies, Overnames

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 jun 2025, 10:47 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 jun 2025, 10:47 UTC

Acquisities, Fusies, Overnames

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 jun 2025, 10:46 UTC

Acquisities, Fusies, Overnames

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 jun 2025, 10:45 UTC

Acquisities, Fusies, Overnames

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 jun 2025, 09:33 UTC

Acquisities, Fusies, Overnames

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11 jun 2025, 09:45 UTC

Marktinformatie

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29 mei 2025, 01:00 UTC

Top Nieuws

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New -2-

28 mei 2025, 18:09 UTC

Winsten

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 mei 2025, 14:02 UTC

Acquisities, Fusies, Overnames

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 mei 2025, 14:01 UTC

Acquisities, Fusies, Overnames

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 mei 2025, 14:00 UTC

Acquisities, Fusies, Overnames

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 mei 2025, 14:00 UTC

Acquisities, Fusies, Overnames

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 mei 2025, 14:08 UTC

Winsten

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 mei 2025, 22:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mei 2025, 18:45 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mei 2025, 17:14 UTC

Top Nieuws

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 mei 2025, 17:01 UTC

Top Nieuws

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mei 2025, 13:56 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 mei 2025, 11:18 UTC

Winsten

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 mei 2025, 09:30 UTC

Top Nieuws

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 mei 2025, 20:30 UTC

Top Nieuws

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 mei 2025, 04:05 UTC

Acquisities, Fusies, Overnames

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 mei 2025, 21:07 UTC

Marktinformatie

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 mei 2025, 14:07 UTC

Winsten

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

Peer Vergelijking

Prijswijziging

Eli Lilly and Co. Prognose

Koersdoel

By TipRanks

28.9% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 999.57 USD  28.9%

Hoogste 1,190 USD

Laagste 700 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Eli Lilly and Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

16

Buy

2

Hold

1

Sell

Technische score

By Trading Central

N/A / 884.54Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

161 / 380 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.